Concepedia

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama, Hideaki Mizutani, Yosuke Uchitomi, Takuhiro Yamaguchi, Yukari Hoshina, Yasuhiko Sakata, Takako Takahashi, Kazuhisa Nakashima,

The Lancet Oncology · 2019 · 235 citations · 16 references

DOI

Concepts

References

16

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

Alain Schotte, Paul Janssen, W Gommeren et al. · Psychopharmacology · 1996 · 1.2K citations · Full text

, , +11

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Frank P. Bymaster, David O. Calligaro, Julie F. Falcone et al. · Neuropsychopharmacology · 1996 · 1.1K citations · Full text

, , +10

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy et al. · New England Journal of Medicine · 2016 · 450 citations · Full text

, , +14

Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial

Rudolph M. Navari, Sarah E. Gray, Andrew C. Kerr · The Journal of Supportive Oncology · 2011 · 316 citations

, , +17

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 248 citations · Full text

, , +17